Abstract 1572P
Background
The determinants of choices of orientation towards medical oncology have been little explored.
Methods
Medical students of the classes 2022 and 2023 in Lille and Amiens Universities (North of France) were enrolled in a quantitative online survey, with 2 follow-up over 2 months. 36 potential determinants from previous works (Wright et al. 2004; Beaulieu et al. 2010) were evaluated using a 5-point Likert scale alongside parameters. Choosing oncology was assessed among 44 specialities. We identified determinants using both CHAID method and binary and multiple linear regressions, and CHAID method.
Results
Responders were 563 (563/1250; 45%). CHAID analysis retained 2 factors: “medical oncology traineeship” (p<.0001) and “identification with a doctor in the specialty” (p=.049). when excluding factors associated with énd-cycle trining, CHAID analysis retained 2 factors associated with a career choice in oncology: “rejection of emergency care” (p=.036) and “wish of hospital-university career” (p=.006). Motivations differed according to sexes. In men, choosing oncology was associated in multivariate analysis with: “hospital traineeship in medical oncology” (β=0.22; p=.010), “hospital traineeship in oncology radiotherapy” (β=0.22; p<0.001) and “interest in fundamental research” (β=0.06; p<.001). Conversely, “rural life” (β=-0.09; p=.014) was negatively associated with this choice. In women, parameters positively associated with choosing oncology were: “hospital traineeship in medical oncology” (β=0.289; p<.001), “long-term relationship with patients” (β=0.12; p=.021) and “hospital work” (β=0.21; p=0<.001). A negative association was observed for: “treatment with visible outcome in the short term” (β=-0.15; p=.018) and “rural life” (β=-0.15; p=.006).
Conclusions
Motivations varied according to sexes. Hospital experience during the second cycle of medical studies plays a determining role. The ability or the interest in emergency management seems important in career choice. Certain interests influence career choice (long-term relationship with patient) as well as contextual factors (rural life). These results can be interpreted according to Bandura's social cognitive theory.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Centre Oscar Lambret.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10